Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Nevada: - OptumCare Cancer Care at Seven Hills — Henderson, Nevada
- OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
- Renown Regional Medical Center — Reno, Nevada
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to o…
Sponsor: Pfizer
NCT ID: NCT07392892
Sites in Nevada: - Renown Health Medical Oncology — Reno, Nevada
- Renown Office of Clinical Research — Reno, Nevada
- Renown Regional Medical Center — Reno, Nevada
Phase 3 Recruiting Industry
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…
Sponsor: AstraZeneca
NCT ID: NCT06764875
Sites in Nevada: - Research Site — Reno, Nevada
Phase 3 Recruiting Industry
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positi…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT06532006
Sites in Nevada: - Comprehensive Cancer Centers Nevada — Las Vegas, Nevada
Phase 2 Recruiting Industry
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06157892
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Nevada: - Women's Cancer Center of Nevada — Las Vegas, Nevada
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Nevada: - Comprehensive Cancer Center of Nevada — Las Vegas, Nevada
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
NA Recruiting Academic/Other
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Nevada: - North Las Vegas VA Medical Center — Las Vegas, Nevada